These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11186514)

  • 1. Prospective value-based assessment of new health care technologies and practices.
    Girod CS; Axene DV
    Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 3. Defining quality health care with outcomes assessment while achieving economic value.
    Shaw LJ; Miller DD
    Top Health Inf Manage; 2000 Feb; 20(3):44-54. PubMed ID: 10747434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology assessment in medicine: methods, status and trends.
    Hendee WR
    Med Prog Technol; 1991; 17(2):69-75. PubMed ID: 1835752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 6. [Health services need knowledge of how the public values health].
    Persson U; Hjelmgren J
    Lakartidningen; 2003 Oct; 100(43):3436-7. PubMed ID: 14626774
    [No Abstract]   [Full Text] [Related]  

  • 7. Pricing life: reflections on the cost of health care.
    Menzel PT
    Hosp Prog; 1982 Jan; 63(1):46-9, 56, 58. PubMed ID: 10309541
    [No Abstract]   [Full Text] [Related]  

  • 8. Quality-adjusted life years: cost-effective medical decision-making.
    Turner S
    J Cardiovasc Manag; 1997; 8(4):34-9. PubMed ID: 10169748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical technology assessment: economic evaluation of new technologies.
    Adang EM; Dirksen CD; Engel GL; Baeten CG
    Br J Hosp Med; 1995 Jun 7-20; 53(11):563-6. PubMed ID: 7655753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and effectiveness: approval and payment for Pulverizer.
    Riegelman R
    Md Med; 2002; 3(3):50-4. PubMed ID: 12214498
    [No Abstract]   [Full Text] [Related]  

  • 11. Group advances method to weigh value of new medical technology.
    Scott L
    Mod Healthc; 1995 Jun; 25(25):78. PubMed ID: 10143112
    [No Abstract]   [Full Text] [Related]  

  • 12. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods of no value must be abandoned.
    Mørland B
    Tidsskr Nor Laegeforen; 2010 Jun; 130(12):1256-7. PubMed ID: 20567280
    [No Abstract]   [Full Text] [Related]  

  • 14. Embedding quality improvement and patient safety: the UCLA value analysis experience.
    Gambone JC; Broder MS
    Best Pract Res Clin Obstet Gynaecol; 2007 Aug; 21(4):581-92. PubMed ID: 17400513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of subjective values to medical technology assessment and health policy.
    Diamond GA
    J Invasive Cardiol; 1993; 5(1):17-22. PubMed ID: 10148297
    [No Abstract]   [Full Text] [Related]  

  • 16. Physician assessment of office-based technologies.
    Magel JS
    Top Health Care Financ; 1992; 18(3):80-8. PubMed ID: 1585360
    [No Abstract]   [Full Text] [Related]  

  • 17. [How much does the society want to pay?].
    Norheim OF
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):303. PubMed ID: 12640893
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating technology under changing financing arrangements.
    Luce BR
    Trustee; 1986 Aug; 39(8):15-7. PubMed ID: 10311653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis and innovation.
    Jena AB; Philipson TJ
    J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.